Clinical Formulation Bridging of Gefapixant, a P2X3‐Receptor Antagonist, for the Treatment of Chronic Cough

por Gupta, Pranav, Hussain, Azher, Ford, Anthony P., Smith, Steven, Nussbaum, Jesse C., Stoch, Aubrey, Iwamoto, Marian
Publicado 2022

Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans

por Nussbaum, Jesse C., Hussain, Azher, Ma, Bennett, Min, K. Chris, Chen, Qing, Tomek, Charles, Iwamoto, Marian, Stoch, S. Aubrey
Publicado 2022

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin

por McCrea, Jacqueline B., Hussain, Azher, Ma, Bennett, Garrett, Graigory C., Evers, Raymond, Laabs, John E., Stoch, S. Aubrey, Iwamoto, Marian
Publicado 2021

Population pharmacokinetic analysis of the P2X3‐receptor antagonist gefapixant

por Chawla, Akshita, Largajolli, Anna, Hussain, Azher, Kleijn, Huub, Ait‐Oudhia, Sihem, Anton, Judith, Krishna Ananthula, Hari, Nussbaum, Jesse, La Rosa, Carmen, Gheyas, Ferdous
Publicado 2023

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

por Muccino, David R., Morice, Alyn H., Birring, Surinder S., Dicpinigaitis, Peter V., Pavord, Ian D., Assaid, Christopher, Kleijn, Huub Jan, Hussain, Azher, La Rosa, Carmen, McGarvey, Lorcan, Smith, Jaclyn A.
Publicado 2020